TY - JOUR
T1 - Effect of Preemptive Intervention on Developmental Outcomes among Infants Showing Early Signs of Autism
T2 - A Randomized Clinical Trial of Outcomes to Diagnosis
AU - Whitehouse, Andrew J.O.
AU - Varcin, Kandice J
AU - Pillar, Sarah
AU - Billingham, Wesley
AU - Alvares, Gail
AU - Barbaro, Josephine
AU - Bent, Catherine A.
AU - Blenkley, Daniel
AU - Boutrus, Maryam
AU - Chee, Abby
AU - Chetcuti, Lacey
AU - Clark, Alena
AU - Davidson, Emma
AU - Dimov, Stefanie
AU - Dissanayake, Cheryl
AU - Doyle, Jane
AU - Grant, Megan
AU - Green , Cherie C.
AU - Harrap, Megan
AU - Iacono, Teresa
AU - Matys, Lisa
AU - Mayberry, Murray
AU - Pope, Daniel
AU - Renton, Michelle
AU - Rowbottam, Catherine
AU - Sadka, Nancy
AU - Segal, Leonie
AU - Slonims, Vicky
AU - Smith , Jodie
AU - Taylor, Carol
AU - Wakeling, Scott
AU - Wan, Ming Wai
AU - Wray, John
AU - Cooper, Matthew N.
AU - Green, Jonathan
AU - Hudry, Kristelle
N1 - PMID: 34542577 PMCID: PMC8453361
Funding Information:
reported developing the Social Attention and Communication Surveillance–Revised outside the submitted work. Dr Blenkley reported receiving personal fees from the University of Manchester during the conduct of the study. Dr Chee reported receiving personal fees from the Child Development Service outside the submitted work. Dr Slonims reported providing input into the development of the iBASIS–Video Interaction to Promote Positive Parenting (iBASIS-VIPP) intervention. Dr Taylor reported providing input into the development of the iBASIS-VIPP intervention and manual outside the submitted work. Dr Wan reported providing input into the development of the iBASIS-VIPP intervention and manual outside the submitted work. Dr J. Green reported owning a patent for the iBASIS-VIPP intervention, being the initiator and codeveloper of the original iBASIS-VIPP manual, receiving personal fees for his role as codirector of IMPACT, and serving as a senior investigator for the United Kingdom National Institute for Health Research outside the submitted work. No other disclosures were reported. Funding/Support: This study was sponsored by the Telethon Kids Institute and supported by grants 1077966 and 1173896 from the National Health and Medical Research Council (Dr Whitehouse) and funding from the Angela Wright Bennett Foundation (Dr Whitehouse), the Telethon-Perth Children’s Hospital Research Fund (Drs Whitehouse, Wray, J. Green, and Segal), the La Trobe University Understanding Disease Research Focus Area (Drs Hudry, Dissanayake, Barbaro, Iacono, Slonims, J. Green, and Whitehouse), and the Cooperative Research Centre for Living with Autism (Autism CRC) established and supported by the Australian government’s Cooperative Research Centre Program (Drs Hudry, Whitehouse, Barbaro, Iacono, Dissanayake, and Maybery).
Publisher Copyright:
© 2021 American Medical Association. All rights reserved.
PY - 2021/11/1
Y1 - 2021/11/1
N2 - Importance: Intervention for individuals with autism spectrum disorder (ASD) typically commences after diagnosis. No trial of an intervention administered to infants before diagnosis has shown an effect on diagnostic outcomes to date.Objective: To determine the efficacy of a preemptive intervention for ASD beginning during the prodromal period.Design, setting, and participants: This 2-site, single rater-blinded randomized clinical trial of a preemptive intervention vs usual care was conducted at 2 Australian research centers (Perth, Melbourne). Community sampling was used to recruit 104 infants aged 9 to 14 months showing early behaviors associated with later ASD, as measured by the Social Attention and Communication Surveillance-Revised. Recruitment occurred from June 9, 2016, to March 30, 2018. Final follow-up data were collected on April 15, 2020.Interventions: Infants were randomized on a 1:1 ratio to receive either a preemptive intervention plus usual care or usual care only over a 5-month period. The preemptive intervention group received a 10-session social communication intervention, iBASIS-Video Interaction to Promote Positive Parenting (iBASIS-VIPP). Usual care comprised services delivered by community clinicians.Main outcomes and measures: Infants were assessed at baseline (approximate age, 12 months), treatment end point (approximate age, 18 months), age 2 years, and age 3 years. Primary outcome was the combined blinded measure of ASD behavior severity (the Autism Observation Scale for Infants and the Autism Diagnostic Observation Schedule, second edition) across the 4 assessment points. Secondary outcomes were an independent blinded clinical ASD diagnosis at age 3 years and measures of child development. Analyses were preregistered and comprised 1-tailed tests with an α level of .05.Results: Of 171 infants assessed for eligibility, 104 were randomized; 50 infants (mean [SD] chronological age, 12.40 [1.93] months; 38 boys [76.0%]) received the iBASIS-VIPP preemptive intervention plus usual care (1 infant was excluded after randomization), and 53 infants (mean [SD] age, 12.38 [2.02] months; 32 boys [60.4%]) received usual care only. A total of 89 participants (45 in the iBASIS-VIPP group and 44 in the usual care group) were reassessed at age 3 years. The iBASIS-VIPP intervention led to a reduction in ASD symptom severity (area between curves, -5.53; 95% CI, -∞ to -0.28; P = .04). Reduced odds of ASD classification at age 3 years was found in the iBASIS-VIPP group (3 of 45 participants [6.7%]) vs the usual care group (9 of 44 participants [20.5%]; odds ratio, 0.18; 95% CI, 0-0.68; P = .02). Number needed to treat to reduce ASD classification was 7.2 participants. Improvements in caregiver responsiveness and language outcomes were also observed in the iBASIS-VIPP group.Conclusions and relevance: Receipt of a preemptive intervention for ASD from age 9 months among a sample of infants showing early signs of ASD led to reduced ASD symptom severity across early childhood and reduced the odds of an ASD diagnosis at age 3 years.Trial registration: http://anzctr.org.au identifier: ACTRN12616000819426.
AB - Importance: Intervention for individuals with autism spectrum disorder (ASD) typically commences after diagnosis. No trial of an intervention administered to infants before diagnosis has shown an effect on diagnostic outcomes to date.Objective: To determine the efficacy of a preemptive intervention for ASD beginning during the prodromal period.Design, setting, and participants: This 2-site, single rater-blinded randomized clinical trial of a preemptive intervention vs usual care was conducted at 2 Australian research centers (Perth, Melbourne). Community sampling was used to recruit 104 infants aged 9 to 14 months showing early behaviors associated with later ASD, as measured by the Social Attention and Communication Surveillance-Revised. Recruitment occurred from June 9, 2016, to March 30, 2018. Final follow-up data were collected on April 15, 2020.Interventions: Infants were randomized on a 1:1 ratio to receive either a preemptive intervention plus usual care or usual care only over a 5-month period. The preemptive intervention group received a 10-session social communication intervention, iBASIS-Video Interaction to Promote Positive Parenting (iBASIS-VIPP). Usual care comprised services delivered by community clinicians.Main outcomes and measures: Infants were assessed at baseline (approximate age, 12 months), treatment end point (approximate age, 18 months), age 2 years, and age 3 years. Primary outcome was the combined blinded measure of ASD behavior severity (the Autism Observation Scale for Infants and the Autism Diagnostic Observation Schedule, second edition) across the 4 assessment points. Secondary outcomes were an independent blinded clinical ASD diagnosis at age 3 years and measures of child development. Analyses were preregistered and comprised 1-tailed tests with an α level of .05.Results: Of 171 infants assessed for eligibility, 104 were randomized; 50 infants (mean [SD] chronological age, 12.40 [1.93] months; 38 boys [76.0%]) received the iBASIS-VIPP preemptive intervention plus usual care (1 infant was excluded after randomization), and 53 infants (mean [SD] age, 12.38 [2.02] months; 32 boys [60.4%]) received usual care only. A total of 89 participants (45 in the iBASIS-VIPP group and 44 in the usual care group) were reassessed at age 3 years. The iBASIS-VIPP intervention led to a reduction in ASD symptom severity (area between curves, -5.53; 95% CI, -∞ to -0.28; P = .04). Reduced odds of ASD classification at age 3 years was found in the iBASIS-VIPP group (3 of 45 participants [6.7%]) vs the usual care group (9 of 44 participants [20.5%]; odds ratio, 0.18; 95% CI, 0-0.68; P = .02). Number needed to treat to reduce ASD classification was 7.2 participants. Improvements in caregiver responsiveness and language outcomes were also observed in the iBASIS-VIPP group.Conclusions and relevance: Receipt of a preemptive intervention for ASD from age 9 months among a sample of infants showing early signs of ASD led to reduced ASD symptom severity across early childhood and reduced the odds of an ASD diagnosis at age 3 years.Trial registration: http://anzctr.org.au identifier: ACTRN12616000819426.
KW - Autism Spectrum Disorder/diagnosis
KW - Early Diagnosis
KW - Early Intervention, Educational
KW - Female
KW - Humans
KW - Infant
KW - Male
KW - Severity of Illness Index
UR - http://www.scopus.com/inward/record.url?scp=85115186907&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/f8acdde3-11b5-35c6-b2cf-71973a94f455/
U2 - 10.1001/jamapediatrics.2021.3298
DO - 10.1001/jamapediatrics.2021.3298
M3 - Article
C2 - 34542577
SN - 2168-6203
VL - 175
SP - 1
EP - 11
JO - JAMA pediatrics
JF - JAMA pediatrics
IS - 11
M1 - e213298
ER -